.jpeg)
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:22:46
Capivasertib is an oral AKT inhibitor used to treat breast cancer and prostate cancer. This article compares the original brand and generic versions from Laos, highlighting differences in price, composition, and considerations for selection.
2026-07-17 07:10:28
This article analyzes the 2026 FDA approval of Selumetinib for adult Neurofibromatosis Type 1 (NF1) with symptomatic plexiform neurofibromas (PN). Covering KOMET Phase III data, BSA-based dosing, hepatic impairment adjustments, and global market availability, it serves as a comprehensive guide for clinicians.
2026-07-16 07:37:00
This guide details the essential baseline evaluations and proactive management strategies for patients starting Lenvatinib therapy. It covers hypertension, proteinuria, hypothyroidism, hand-foot skin reactions, cardiac monitoring, and drug interactions.
2026-07-15 07:25:49
This guide provides global patients with comprehensive information on Inluriyo, covering its active ingredient, mechanism of action, eligible population, dosing guidelines, and safety precautions.
2026-07-14 05:31:14
Idelalisib is an oral PI3Kδ inhibitor indicated for relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The recommended dose is 150 mg twice daily. Close monitoring for severe hepatic, pulmonary, and intestinal toxicities, as well as life-threatening diarrhea, is required. This article covers indications, dosing, warnings, and adverse reactions.
2026-07-14 05:26:41
Lorlatinib is an oral tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended dose is 100 mg once daily. Treatment must be initiated by a physician experienced in anticancer therapy and preceded by ALK genetic testing. This article covers dosing, mechanism of action, common side effects, and key contraindications.
2026-07-13 07:43:38
On June 24, 2026, the FDA approved Pfizer’s Ibrance (palbociclib) in combination with anti-HER2 therapy and endocrine therapy for maintenance treatment of HR+/HER2+ advanced breast cancer, based on Phase III PATINA trial results.
2026-07-13 07:34:24
The U.S. FDA approved Gilead’s Trodelvy (sacituzumab govitecan) on June 24, 2026, for first-line treatment of advanced triple-negative breast cancer (TNBC), based on Phase III ASCENT-03 and ASCENT-04 data.
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
